Omnicell's (OMCL) Neutral Rating Reaffirmed at Bank of America

Bank of America reaffirmed their neutral rating on shares of Omnicell (NASDAQ:OMCL - Free Report) in a research note issued to investors on Thursday, Marketbeat Ratings reports. They currently have a $57.00 price target on the stock, up from their prior price target of $44.00.

Several other analysts have also issued reports on OMCL. Barclays upgraded shares of Omnicell from an "underweight" rating to an "equal weight" rating and upped their price target for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Benchmark restated a "buy" rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. StockNews.com upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Saturday, October 19th. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $26.00 to $37.00 and gave the stock a "neutral" rating in a report on Friday, August 23rd. Finally, Wells Fargo & Company increased their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a report on Monday, October 14th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $49.14.

Omnicell Price Performance

NASDAQ:OMCL traded down $4.41 during midday trading on Thursday, hitting $48.64. The company had a trading volume of 1,061,254 shares, compared to its average volume of 527,409. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The stock's fifty day moving average price is $43.26 and its 200-day moving average price is $35.17. The company has a market capitalization of $2.24 billion, a PE ratio of -124.72, a P/E/G ratio of 43.55 and a beta of 0.83. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. During the same period in the prior year, the business posted $0.29 earnings per share. The company's revenue was down 7.4% on a year-over-year basis. As a group, research analysts expect that Omnicell will post 0.64 earnings per share for the current year.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its stake in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock worth $55,000 after buying an additional 553 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company's stock worth $38,000 after buying an additional 1,000 shares in the last quarter. 1620 Investment Advisors Inc. raised its stake in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock worth $96,000 after buying an additional 1,542 shares in the last quarter. EntryPoint Capital LLC increased its stake in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company's stock valued at $72,000 after purchasing an additional 1,345 shares in the last quarter. Finally, CWM LLC increased its stake in shares of Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company's stock valued at $83,000 after purchasing an additional 1,236 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.